60003-47-6

Upstream product

• 156-38-7 4-hydroxyphenylacetate 
• 29056-06-2 (4-butoxy-phenyl)-acetic acid methyl ester 
• 4547-57-3 4-butoxyphenylacetic acid 

Downstream Products

• 89789-99-1 2-(4-Butoxy-phenyl)-N-methyl-acetamide 
• 89790-00-1 N,N-dimethyl-p-butoxyphenylacetamide 
• 345321-78-0 2-(4-Butoxy-phenyl)-1-(4-hexyl-phenyl)-ethanone 
• 88210-73-5 norethisterone 4-(butoxy)phenylacetate 
• 50690-60-3 4-butoxybenzyl phenyl ketone 
• 33096-49-0 1-butoxy-4-(isocyanatomethyl)benzene 
• 359881-95-1 2-(4-butoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)acetamide hydrochloride 
• 137619-25-1 {2-(4-Butoxy-phenyl)-1-[(Z)-hydroxyimino]-ethyl}-phosphonic acid diethyl ester 
• 137619-41-1 [1-Amino-2-(4-butoxy-phenyl)-ethyl]-phosphonic acid diethyl ester 
• 137619-63-7 [1-Amino-2-(4-butoxy-phenyl)-ethyl]-phosphonic acid 
• 344268-06-0 4-(4-Butoxy-phenyl)-3-(4-hexyl-phenyl)-3-hydroxy-butyric acid ethyl ester 
• 83787-76-2 7-Butoxy-3-(4-hexyl-phenyl)-3,4-dihydro-2H-naphthalen-1-one 
• 344253-27-6 4-(4-Butoxy-phenyl)-3-(4-hexyl-phenyl)-butyric acid ethyl ester 
• 344249-14-5 4-(4-Butoxy-phenyl)-3-(4-hexyl-phenyl)-butyric acid 

Relevant academic research and scientific papers

COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES

The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES

The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.

AZACYCLIC COMPOUNDS

Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS

Inverse agonists and antagonists of serotonin receptors are disclosed for use in treating sleep disorders such as insomnia, and specifically sleep maintenance insomnia. The compound increase slow wave sleep, decrease the number of awakenings after sleep onset, and decrease the time awake after sleep onset.

Design of Inhibitors from the Three-Dimensional Structure of Alcohol Dehydrogenase. Chemical Synthesis and Enzymatic Properties

Inhibitors of liver alcohol dehydrogenase were designed from the three-dimensional structure of the enzyme.The ligand to the catalytic zinc ion is an amide group or, better, a formamide group.With the latter function, a hydrogen bond between the NH group and the hydroxyl group of Ser-48 may be formed.The hydrophobic substrate binding site brings structural restraints. α-ω bifunctional molecules show good inhibitory properties possibly due to the interactions with polar residues at the entrance of the substrate binding site.

LONG-ACTING CONTRACEPTIVE AGENTS: NORETHISTERONE ESTERS OF ARYLCARBOXYLIC ACIDS

The synthesis of esters of norethisterone (17α-ethynyl-17β-hydroxyestr-4-en-3-one) with acids containing a benzene ring is described, two methods of esterification being compared in terms of yield and convenience.The activities of these esters as long-acting contraceptive agents have been evaluated.

Synthesis and Mesomorphic Properties of 2,6-Disubstituted Tetralins

Synthesis and mesomorphic behavior of nine members of each of the two classes of 6-phenyl- and 2-phenyltetralins and five members of the 2-trans-cyclohexyltetralins are reported.The synthesis of one member of each class is described in detail.Besides the target compounds, more than twenty intermediates showed liquid crystalline properties; their transition temperatures are recorded (see Tables 1-6).